News

MyChesCo on MSN15h
DESTINY-Breast09 Trial Demonstrates Promising Results for ENHERTU in Combination with Pertuzumab
Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...
Fierce Pharma10d
AstraZeneca, Daiichi say Enhertu delivers 'highly statistically significant' efficacy in first-line breast cancer
AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...
Applied Clinical Trials Online10d
DESTINY-Breast09 Trial Shows Enhertu Plus Perjeta Significantly Improves Survival in HER2-Positive Metastatic Breast Cancer
In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...
BioPharma Dive10d
Enhertu combo tops standard drugs in first-line HER2 breast cancer
The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...
Fierce Pharma6d
Fierce Pharma Asia—Enhertu's first-line win; Akeso bispecific's positive readout; Regeneron, Fujifilm's $3B deal
AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...
BioSpace9d
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data
Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...
Yahoo Finance9d
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics ... 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and multiple-ascending ...
Nasdaq1mon
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the DESTINY-Gastric05 phase ... 1. An exploratory cohort of patients with PD-L1 CPS 1% of patients who received ...